Российская тест-система РСА3: первые результаты

Российская тест-система РСА3: первые результаты

Автор: Сидоренков А.В., Говоров А.В., Пушкарь Д.Ю., Павлов К.А., Шкопоров А.Н., Хохлова Е.В., Корчагина А.А., Григорьев М.Э., Чехонин В.П.

Журнал: Экспериментальная и клиническая урология @ecuro

Рубрика: Онкоурология

Статья в выпуске: 2, 2014 года.

Бесплатный доступ

Рак предстательной железы, биомаркер, от-пцр, пцр в режиме реального времени

Короткий адрес: https://sciup.org/142188377

IDR: 142188377

Список литературы Российская тест-система РСА3: первые результаты

  • Говоров А.В. Оптимизация трансректальной биопсии простаты в диагностике рака предстательной железы: Автореф. дис.. канд. мед. наук. М., 2002. 17 с.
  • Hodge K.K., McNeal J.E., Terris M.K., Stamey T.A. Random systematic versus directed ultrasound guided transrectal core biopsies of the prostate.//J Urol. 1989. Vol. 142. P. 71-75.
  • Hammerer P., Huland H. Systemic sextant biopsies in 651 patients referred for prostate evaluation.//J Urol. 1994. Vol. 151, N 1. P. 99-102.
  • Svetec D., McCabe K., Peretsman S., Klein E., Levin H., Optenberg S., Thompson I. Prostate rebiopsy is a poor surrogate of treatment efficacy in localized prostate cancer.//J Urol. 1998. Vol. 159, N 5. P. 1606-1608.
  • Guichard G., Larré S., Gallina A., Lazar A., Faucon H., Chemama S., Allory Y., Patard J.J., Vordos D., Hoznek A., Yiou R., Salomon L., Abbou C.C., de la Taille A. Extended 21-sample needle biopsy protocol for diagnosis of prostate cancer in 1000 consecutive patients.//Eur Urol. 2007. Vol. 52. P 430-435.
  • Singh H., Canto E.I., Shariat S.F., Kadmon D., Miles B.J., Wheeler T.M., Slawin K.M. Predictors of prostate cancer after initial negative systematic 12 core biopsy.//J Urol. 2004. Vol. 171. P. 1850-1854.
  • Olivier C., Bernard М. Biomarkers of Aggressiveness in Prostate Cancer.//in book “Prostate Cancer -Diagnostic and Therapeutic Advances” [Ed. Dr. Philippe E. Spiess]. 2011. P. 3-20.
  • Bussemakers M.J., van Bokhoven A., Verhaegh G.W., Smit F.P., Karthaus H.F., Schalken J.A., Debruyne F.M., Ru N., Isaacs W.B. DD3: a new prostate-specific gene, highly overexpressed in prostate cancer.//Cancer Res. 1999. Vol. 59, N 23. P. 5975-5979.
  • Bourdoumis A., Papatsoris A.G., Chrisofos M., Efstathiou E., Skolarikos A., Deliveliotis C. The novel prostate cancer antigen 3 (PCA3) biomarker.//Int Braz J Urol. 2010. Vol. 36, N 6. P. 665-668.
  • Day J.R., Jost M., Reynolds M.A., Groskopf J., Rittenhouse H. PCA3: from basic molecular science to the clinical lab.//Cancer Lett. 2011. Vol. 301, N 1. P. 1-6.
  • de Kok J.B., Verhaegh G.W., Roelofs R.W., Hessels D., Kiemeney L.A., Aalders T.W., Swinkels D.W., Schalken J.A. DD3 (PCA3), a very sensitive and specific marker to detect prostate tumors.//Cancer Res. 2002. Vol. 62, N 9. P. 2695-2698.
  • Fradet Y., Saad F., Aprikian A., Dessureault J., Elhilali M., Trudel C., Mâsse B., Piché L., Chypre C. uPM3, a new molecular urine test for the detection of prostate cancer.//Urology. 2004. Vol. 64, N 2. P. 311-315.
  • Tinzl M., Marberger M., Horvath S., Chypre C. DD3 PCA3 RNA analysis in urine-a new perspective for detecting prostate cancer.//Eur Urol. 2004. Vol. 46, N 2. P. 182-186.
  • Deras I.L., Aubin S.M., Blase A., Day J.R., Koo S., Partin A.W., Ellis W.J., Marks L.S., Fradet Y., Rittenhouse H., Groskopf J. PCA3: a molecular urine assay for predicting prostate biopsy outcome.//J Urol. 2008. Vol. 179, N 4. P 1587-1592.
  • Groskopf J., Aubin S.M., Deras I.L., Blase A., Bodrug S., Clark C., Brentano S., Mathis J., Pham J., Meyer T., Cass M., Hodge P., Macairan M.L., Marks L.S., Rittenhouse H. APTIMA PCA3 molecular urine test: development of a method to aid in the diagnosis of prostate cancer.//Clin Chem. 2006. Vol. 52, N 6. P 1089-1095.
  • Haese A., de la Taille A., van Poppel H., Marberger M., Stenzl A., Mulders P.F., Huland H., Abbou C.C., Remzi M., Tinzl M., Feyerabend S., Stillebroer A.B., van Gils M.P., Schalken J.A. Clinical utility of the PCA3 urine assay in European men scheduled for repeat biopsy.//Eur Urol. 2008. Vol. 54, N 5. P 1081-1088.
  • Marks L.S., Bostwick D.G. Prostate Cancer Specificity of PCA3 Gene Testing: Examples from Clinical Practice.//Rev Urol. 2008. Vol. 10, N 3. P. 175-181.
  • van Gils M.P., Hessels D., van Hooij O., Jannink S.A., Peelen W.P., Hanssen S.L., Witjes J.A., Cornel E.B., Karthaus H.F., Smits G.A., Dijkman G.A., Mulders P.F., Schalken J.A. The time-resolved fluorescence-based PCA3 test on urinary sediments after digital rectal examination; a Dutch multicenter validation of the diagnostic performance.//Clin Cancer Res. 2007. Vol. 13, N 3. P 939-943.
  • van Gils M.P., Hessels D., Hulsbergen-van de Kaa C.A., Witjes J.A., Jansen C.F., Mulders P.F., Rittenhouse H.G., Schalken J.A. Detailed analysis of histopathological parameters in radical prostatectomy specimens and PCA3 urine test results.//Prostate. 2008. Vol. 68. P 1215-1222.
  • Auprich M., Chun F.K., Ward J.F., Pummer K., Babaian R., Augustin H., Luger F., Gutschi S., Budäus L., Fisch M., Huland H., Graefen M., Haese A. Critical assessment of preoperative urinary prostate cancer antigen 3 on the accuracy of prostate cancer staging.//Eur Urol. 2011. Vol. 59. P 96-105.
  • van Poppel H., Haese A., Graefen M., de la Taille A., Irani J., de Reijke T., Remzi M., Marberger M. The relationship between Prostate CAncer gene 3 (PCA3) and prostate cancer significance.//BJU Int. 2012. Vol. 109, N 3. P. 360-366.
  • Chun F.K., de la Taille A., van Poppel H., Marberger M., Stenzl A., Mulders P.F., Huland H., Abbou C.C., Stillebroer A.B., van Gils M.P., Schalken J.A., Fradet Y., Marks L.S., Ellis W., Partin A.W., Haese A. Prostate cancer gene 3 (PCA3): Development and internal validation of a novel biopsy nomogram.//Eur Urol. 2009. Vol. 56. P. 659-668.
  • Wu A.K., Reese A.C., Cooperberg M.R., Sadetsky N., Shinohara K. Utility of PCA3 in patients undergoing repeat biopsy for prostate cancer.//Prostate Cancer Prostatic Dis. 2012. Vol. 15. P 100-105.
  • Hansen J., Auprich M., Ahyai S.A., de la Taille A., van Poppel H, Marberger M., Stenzl A., Mulders P.F., Huland H., Fisch M. Initial prostate biopsy: Development and internal validation of a biopsy-specific nomogram based on the prostate cancer antigen 3 assay.//Eur Urol. 2013. Vol. 63. P 201-209.
  • Ruffion A., Devonec M., Champetier D., Decaussin-Petrucci M., Rodriguez-Lafrasse C., Paparel P., Perrin P., Vlaeminck-Guillem V. PCA3 and PCA3-Based nomograms improve diagnostic accuracy in patients undergoing first prostate biopsy.//Int J Mol Sci. 2013. Vol. 14, N 9. P. 17767-17780.
  • Schilling D., Hennenlotter J., Munz M., Bökeler U., Sievert K.D., Stenzl A. Interpretation of the prostate cancer gene 3 in reference to the individual clinical background: implications for daily practice.//Urol Int. 2010. Vol. 85, N 2. P. 159-165.
  • Galasso F., Giannella R., Bruni P., Giulivo R., Barbini V.R., Disanto V., Leonardi R., Pansadoro V., Sepe G. PCA3: a new tool to diagnose prostate cancer (PCa) and a guidance in biopsy decisions. Preliminary report of the UrOP study.//Arch Ital Urol Androl. 2010. Vol. 82, N 1. P. 5-9.
Еще
Статья
QR-код для установки приложения SciUp Наведите камеру и скачайте бесплатное приложение SciUp